Skip to Content
Diagnosed with AS? Biologics can help >

Allopurinol / lesinurad Pregnancy and Breastfeeding Warnings

Allopurinol / lesinurad is also known as: Duzallo

Allopurinol / lesinurad Pregnancy Warnings

Safety has not been established during pregnancy. US FDA pregnancy category: Not assigned. Risk summary: No data available on use of this drug in pregnant women to inform a drug-related risk.

Animal studies have failed to reveal evidence of teratogenicity and fetotoxicity at allopurinol and lesinurad doses reaching maternal toxicity. Allopurinol has been teratogenic and produced fetal deaths in animals with intraperitoneal administration. There are no controlled data in human pregnancy. US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

See references

Allopurinol / lesinurad Breastfeeding Warnings

Benefit to mother should outweigh risk to the infant. Excreted into human milk: Yes (allopurinol); Unknown (lesinurad) Excreted into animal milk: Yes (lesinurad) Comments: -The effects of allopurinol in the nursing infant are unknown. -The WHO considers allopurinol compatible with breastfeeding.

See references

References for pregnancy information

  1. "Product Information. Duzallo (allopurinol-lesinurad)." Ironwood Pharmaceuticals, Inc, Cambridge, MA.

References for breastfeeding information

  1. Department of Adolescent and Child Health and Development. UNICEF. World Health Organization "Breastfeeding and maternal medication: recommendations for drugs in the eleventh Who model list of essential drugs. Available from: URL:" ([2003]):
  2. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):
  3. "Product Information. Duzallo (allopurinol-lesinurad)." Ironwood Pharmaceuticals, Inc, Cambridge, MA.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.